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Results. The primary analysis was conducted on 99 mizori-A multicenter trial of mizoribine compared with placebo in
bine- and 98 placebo-treated patients. The relapse rate waschildren with frequently relapsing nephrotic syndrome.
lower in the mizoribine group than in the placebo group (0.0055Background. The use of corticosteroids or cytotoxic/immu-
vs. 0.0067; ratio 0.81, 95% CI, 0.61 to 1.05, P 5 0.12). Thenosuppressive agents such as cyclophosphamide, chlorambucil,
hazard ratio of the cumulative remission rate between the twoand cyclosporine for the treatment of frequently relapsing ne-
groups was 0.79 (95% CI, 0.57 to 1.08). In the subgroups con-phrotic syndrome (FRNS) is limited because of their adverse
sisting of patients 10 years old or younger, the relapse rateeffects. This study was conducted to evaluate the efficacy and ratio between the mizoribine subgroup (54 patients) and the
safety of mizoribine, a relatively new immunosuppressive drug placebo subgroup (57 patients) was 0.66 (95% CI, 0.44 to 0.94,
developed in Japan, in children with FRNS. P 5 0.017). The hazard ratio of the cumulative remission rate
Methods. A double-blind, placebo-controlled, multicenter between the two subgroups was 0.56 (95% CI, 0.37 to 0.85,
trial was carried out in children, from 2 to 19 years old, with P 5 0.007). Hyperuricemia was the most common adverse
FRNS. At relapse, patients were treated with prednisolone. event with mizoribine (16%), but was transient.
According to a dynamic allocation, mizoribine or a placebo Conclusions. Compared with the placebo, mizoribine signifi-
cantly decreased the relapse rate and prolonged the remissionwas concurrently administered to each patient. Prednisolone
period in the subgroup consisting of patients 10 years old orwas gradually tapered and discontinued within 12 weeks. The
younger. This drug may be useful in young children with FRNStest drug was maintained for 48 weeks. The primary end point
who generally relapse more frequently than older children.was the relapse rate (the total number of relapses/the total
treatment days for all patients). Analyses were performed ac-
cording to the intention-to-treat principle.
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The introduction of corticosteroids markedly im- METHODS
proved the prognosis of primary nephrotic syndrome in Patients
children. Once remission is achieved by steroid therapy, A total of 210 patients from 57 centers throughout
a significant proportion of patients exhibits subsequent Japan were considered for enrollment in our study. Pa-
relapses [1, 2]. Continuous or repeated use of steroids tients were eligible if they met all of the inclusion criteria
inevitably induces growth failure, cataracts, hyperten- as follows: primary nephrotic syndrome with three or
sion, and osteoporotic bone disease. Cytotoxic or immu- more relapses in the past 12 months or two times or
nosuppressive agents such as cyclophosphamide [3–5], more in the past six months, and age over 2 and less than
chlorambucil [6], cyclosporine [7, 8], and levamisole [9] 18. Exclusion criteria included the following: previous
are used to induce lasting remission, thereby sparing the treatment with cytotoxic drugs, other immunosuppres-
patient further exposure to corticosteroids. These drugs sive agents, levamisole, or antihuman lymphocyte globu-
have acute and chronic side effects, including leukope- lin in the recent six months; renal dysfunction (creatinine
nia, infection, hemorrhagic cystitis, alopecia, infertility, clearance of #50 mL/min/1.73 m2 or serum creatinine of
and late occurrence of malignancy for cyclophospha- $1.5 mg/dL); secondary nephrotic syndrome; and preg-
mide, central nervous system disorders, gonadal toxicity, nancy.
and risk of hematological malignancy for chlorambucil, The definition and criteria of nephrotic syndrome used
nephrotoxicity for cyclosporine [1, 2, 10–12], and neutro- here are those defined by the International Study of
penia or rarely agranulocytosis in levamisole [9]. Effec- Kidney Diseases in Children [29]. Remission was defined
tive and safe drugs are needed for the treatment of fre- as a reduction in proteinuria to less than 10 mg/dL or
quently relapsing nephrotic syndrome (FRNS). qualitative resolution of proteinuria (negative by dip-
Mizoribine (bredinin; 4-carbamoyl-1-b-D-ribofurano- stick method) for three consecutive days with normal
sylimidazolium) is an imidazole nucleotide originally iso- levels of serum albumin and cholesterol. Relapse was
lated from a soil fungus, Eupenicillium brefeldianum, in defined as the condition in which urinary protein in early
Japan [13] and is an effective immunosuppressant [14, morning urine exceeded 100 mg/dL or 21 or above by
15]. Mizoribine blocks the purine biosynthesis pathway the dipstick method for at least three consecutive days.
[16, 17] and inhibits mitogen-stimulated T- and B-cell Steroid-dependence was defined as the condition in
proliferation [16, 18–21]. Experimental studies showed which relapse occurred at the tapering of the steroid
that mizoribine favorably influenced the course of lupus dosage or within 14 days after the termination of steroids.
nephritis in NZB/W F1 mice [21], antiglomerular base-
ment membrane antibody-mediated nephritis in rabbits Study design
[22], and IgA nephropathy in ddy mice [23]. The clinical We used centralized, computer-generated dynamic al-
efficacy of mizoribine was first approved in renal trans- location to balance the following baseline characteristics
plant recipients [24]. Controlled trials conducted in Ja- between mizoribine group and placebo group: (1) the
pan demonstrated that this drug prolonged graft survival center, (2) age (10 years or younger, 11 years or older),
without myelosuppression or hepatotoxicity [25]. Con- (3) relapse frequency in the past, (4) history of immuno-
trolled studies further revealed the efficacy of mizoribine suppressive therapy including cyclosporine, and (5) ste-
in the treatment of patients with lupus nephritis [26], roid dependency (Table 1). The allocation code was not
rheumatoid arthritis [27], and steroid-resistant nephrotic broken until all patients had completed the follow-up
syndrome [28]. period. All eligible patients or their parents gave written
Previously, we conducted an open-labeled trial in 44 informed consent to take part in the study. Appropriate
children with FRNS (unpublished observations). Pa- ethics committee approval was obtained for each center.
tients at the relapse were treated with prednisolone plus Administration of the test drug was started when re-
mizoribine. The steroid therapy was tapered and discon- lapse occurred. After a relapse had been confirmed, pa-
tinued as described for the preceding relapse. Mizoribine tients were first treated with prednisolone at a dose of
was given at a daily dose of 2 to 5 mg/kg for 24 weeks, 1.0 to 2.0 mg/kg for consecutive 28 days. The dose was
and the patients were followed up for an additional 24 gradually reduced every week and discontinued within
weeks. The relapse rate (the number of relapses during 12 weeks. Mizoribine or a matching placebo was started
the study period), compared between 48 weeks before within two weeks after the initiation of the steroid ther-
and after the mizoribine therapy, was significantly de- apy for relapse. According to the patient’s height, the
creased after the therapy (unpublished observations). body weight was calculated based on the standard height-
No case showed any serious side effects. Therefore, we weight table in Japan 1988. Mizoribine or placebo at a
performed a multicenter, prospective, double-blind study daily dose of 4 mg/kg was orally given divided into two
to compare mizoribine with a placebo in the manage- doses and was maintained for 48 weeks.
Patients were re-examined once a month after thement of children with FRNS.
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Table 1. Baseline characteristics of patients An interim analysis was performed at the point when
half of the targeted number of patients was observed forMizoribine Placebo
(N 5 99) (N 5 98) P value 24 weeks. Continuation of the trial was determined under
Sex the recommendation of Independent Data Monitoring
Male 72 70 0.84a Committee (IDMC).
Female 27 28
Agee years
Statistical analysis0–5 18 22
6–10 36 35 0.46b Based on the results of the phase II study, the accumu-11–15 35 33
lated remission rate after the 48-week treatment dura-161 10 8
Duration of illness years tion of test drugs was assumed to be 25% in the mizori-
,1 19 21 bine group and 12% in the placebo group. The estimated,3 24 29 0.46b
sample size was 100 patients in each group at a 5% two-,6 28 22
$6 28 26 sided significance level with a power of 80%.
Disease typee Analyses were performed according to the intention-Steroid-dependent 90 90 0.82a
Nonsteroid-dependent 9 8 to-treat principle. The primary end point of this study
Renal biopsy was the relapse rate, defined as the total number of
Not performed 57 55
relapses divided by the duration of observation for allPerformede 0.76a
Minimal change 39 38 patients in each treatment group. The ratio of the relapse
Othersc 3 5 rate of two groups was statistically tested by the permuta-
Number of previous relapsese
tion method. Four patients (two in each group) were2 times/24 weeks 26 31
3 times/48 weeks 39 35 0.70a excluded from this analysis because they did not achieve
$4 times/48 weeks 34 32 remission after allocation and continuous use of steroids
History of other immunosuppressants at least 6 months before the with test drugs. The cumulative remission rate was calcu-
studyd (some overlapped)
lated using the period until the first relapse with theImmunosuppressantse
yes 39 42 0.62a Kaplan–Meier method and was compared with the log-
no 60 56 rank test. In this analysis, the four patients who did
Cyclosporinee
not achieve remission after allocation were included andyes 14 14 0.98a
no 85 84 treated as they relapsed at the start of the observation
Cyclophosphamide period. The permutation test and log-rank test were ad-yes 34 38 0.52a
justed for the number of previous relapses. The baselineno 65 60
characteristics of the patients between the two groupsa x2 test
b Wilcoxon test were compared by a chi-square test or Wilcoxon test.
c Focal segmental glomerulosclerosis in 2 (1: mizoribine; 1: placebo) and mes-
Since 0.2% of type I error was spent at the interim analysis,angial proliferative glomerulonephritis in 6 (2: mizoribine; 4: placebo)
d Patients treated with immunosuppressants in the recent 6 months were ex- the two-sided significance level of the primary end point
cluded from the study
was decided to be 4.8% at the final analysis. All of thee Used as balancing factors for allocation
analyses were done with SAS software (version 6.10).
Relapse risk index
start of treatment. Urinalysis and blood pressure were
We searched for risk factors associated with predispo-checked at every visit. We assessed standard hematologi-
sition to future relapse using logistic regression tech-cal and biochemical tests, including serum creatinine,
niques. We included in the regression models those vari-blood urea nitrogen, and uric acid, every three months.
ables found in the baseline characteristics as follows:The creatinine clearance and serum IgG level were also
gender, age at time of treatment, duration of illness be-assessed every three months. Height and body weight
fore treatment, steroid dependency, renal biopsy find-were measured at the beginning and end of the study.
ings, the number of relapses in the past, dose of steroidsThe subjects were asked about adverse events and com-
taken by the patient at the latest relapse, and the historypliance at each visit. Withdrawal from treatment could
of other immunosuppressive therapy. As risk factors,result because of lack of efficacy, serious adverse events,
three variables, the number of relapses in the past, dura-or the patient’s request. Whenever possible, those who
tion of illness, and dose of steroids taken by a patient athad withdrawn were encouraged to attend the final study
the latest relapse were selected by the stepwise method.visit. Relapse during the study period was treated with
The relapse risk index was defined as the value of linearprednisolone, similar to the protocol applied to the re-
predictor calculated by the logistic regression method withlapse at start of the trial. Patients were followed up for
these three variables for each patient. A larger value ofan additional six months after the discontinuation of
treatment with the test drugs. the index indicated a higher risk of relapse.
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Fig. 1. Trial profile. Two patients in each group were excluded from the analysis of the relapse rates because they did not achieve remission after
allocation.
RESULTS rate was 0.0055 in the mizoribine group and 0.0067 in
the placebo group. The ratio of the relapse rates wasStudy population
0.81 (95% CI, 0.61 to 1.05, P 5 0.12). The cumulative
Of 210 patients screened for eligibility, 9 patients did remission rate was calculated on a total of 197 patients
not meet the inclusion criteria (Fig. 1). Allocation was (99 patients in the mizoribine group and 98 patients in
performed in the 201 patients. At the end of the trial, four the placebo group). In this analysis, the four patients
patients were excluded because of a lack of eligibility who did not achieve remission after allocation were in-
evaluated before key opening. The remaining 197 patients cluded and treated as they relapsed at the start of the
(99 patients in the mizoribine group, 98 patients in the observation period. The hazard ratio of cumulative re-
placebo group) were analyzed on an intention-to-treat mission rate between the two groups was 0.79 (95% CI,
policy. The administration of test drugs was discontinued 0.57 to 1.08, P 5 0.13; Fig. 2).
early in five patients in the mizoribine group and nine
patients in the placebo group and was maintained for Subgroup analysis
more than 12 weeks in the remaining 183 patients (92.9%). To identify the subgroups in which the test drug was
The groups were well matched in terms of baseline effective, the relapse rate ratio, hazard ratio of the cumu-
characteristics (Table 1). As shown, 180 of the 197 pa- lative remission rate, and 95% confidence intervals were
tients (91.4%) were steroid dependent. Renal biopsy calculated depending on each baseline characteristic (Ta-
revealed minimal changes in 77 of 85 patients (90.6%). ble 2). In the subgroup of patients aged 10 years or
Immunosuppressive or cytotoxic drugs were previously younger, the relapse rate was significantly lower in the
administered in 81 of the 197 patients (41.1%). mizoribine group (54 patients) than the placebo group
(57 patients, ratio 0.66, 95% CI 0.44 to 0.94, P 5 0.017).
Clinical efficacy The hazard ratio of the cumulative remission rate be-
The relapse rates were calculated for a total of 193 tween the mizoribine and placebo subgroups consisting
patients (97 patients in the mizoribine group and 96 of children aged 10 years or younger was 0.56 (95% CI,
patients in the placebo group), excluding 4 patients (2 0.37 to 0.85, P 5 0.007; Fig. 3). In this subgroup, the
in each group) who did not achieve remission after the daily dosage of steroids in the study period was signifi-
cantly lower in the mizoribine group than in the placeboinitiation of the test drug (Methods section). The relapse
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Fig. 2. Relapse rate (A) and cumulative re-
mission rate (B) in mizoribine and placebo
groups. Hazards ratio 5 0.79; P 5 0.13.
Table 2. Relapse rate ratio and 95% confidence intervals (CI) in aged 10 years or younger. There was no significant differ-
the patients grouped according to the baseline characteristics
ence in the relapse rate or cumulative remission period
Relapse rate ratio between the mizoribine group and the placebo group in
Baseline characteristic of patients (mizoribine/placebo) 95% CI the subgroups of patients aged 11 years or older.
Total patients 0.81 0.61–1.05
Age Relapse risk index
#10 years 0.66 0.44–0.94
$11 years 1.12 0.73–1.72 To determine the reason that mizoribine showed a dif-
Duration of illness ferent efficacy according to the patients’ age, the preva-
,1 year 0.97 0.59–1.58
lence of relapses (relapse risk index) was investigated. The$1 years 0.80 0.57–1.08
Number of previous relapse relapse risk index, calculated in each patient by multiple-
(times/weeks) regression models (Methods section), was similarly dis-
2/24 0.72 0.42–1.11
tributed in the mizoribine and placebo groups. Irrespec-3/48 0.96 0.60–1.55
$4/48 0.78 0.46–1.22 tive of which drug was given, mizoribine or placebo, the
History of immunosuppressants relapse risk was greater in the patients 10 years old or
yes 0.74 0.45–1.16
younger than in patients 11 years old or older (Fig. 4).no 0.87 0.61–1.21
Prednisolone dose at the last There was no direct relationship between the patient’s
relapse mg/kg/day age and other factors such as the number of relapses in
,0.4 0.80 0.54–1.14
the past, the duration of illness, and steroid dosage at$0.4 0.85 0.55–1.27
the latest relapse. It seems that the age collectively repre-
sents relapse risk generalized by these factors.
Safetygroup [0.65 6 0.33 (SD) vs. 0.83 6 0.44 (SD), P 5 0.017].
Adverse events were observed in 33 of 99 patientsThere was no imbalance in baseline characteristics, in-
(33%) in the mizoribine group and 21 of 98 patientscluding gender, duration of illness, steroid dependency,
(21%) in the placebo group (Table 3). No significantrenal biopsy findings, number of previous relapses, or
differences were noted in the prevalence of adversehistory of other immunosuppressive drugs, between the
mizoribine and placebo subgroups consisting of children events except hyperuricemia, which occurred more fre-
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Fig. 3. Relapse rate (A) and cumulative re-
mission rate (B) in the subgroup of patients
aged 10 years or younger at the start of the
trial. Hazards ratio 5 0.56; P 5 0.007.
quently in the mizoribine group (16 patients) than in effective. Dividing the group by patient age, one of the
balancing factors for allocation, we found that the relapsethe placebo group (4 patients). In the mizoribine group,
rate and cumulative remission rate significantly improvedhyperuricemia mostly occurred within eight weeks after
after mizoribine administration in the subgroup consistingthe start of the trial. Mizoribine was discontinued in one
of patients aged 10 years or younger. There was no differ-patient because of the elevation of serum uric acid level
ence in the effect between mizoribine and placebo in theto 21.2 mg/dL after the trial from 10.7 mg/dL before. The
older subgroup, probably because the relapse risk ofadministration of the drug was temporarily suspended in
children with nephrotic syndrome decreases with age astwo patients, and the dosage was reduced in one patient,
a natural course. Our analysis using the relapse risk indexwhile the initial dosage was maintained in the remaining
showed that younger children had a higher risk of re-12 patients. The serum uric acid level gradually returned
lapse. The age was not confounded with other factors.to the normal level in the 15 patients, and then the
Previous studies pointed out that in children with steroid-trial safely continued. Renal calculi were noticed in one
sensitive nephrotic syndrome, a younger age is a predis-patient of the mizoribine group who had renal stones in
posing factor to a lengthy relapsing course [30, 31]. Bar-the past history but not on allocation. No serious adverse
ratt et al analyzed baseline characteristics that mightevents were noted in either group.
influence the relapse rate in patients with FRNS treated
with cyclophosphamide [5]. They found that age at the
DISCUSSION time of treatment affected the time to relapse (longer
This trial was planned to confirm and extend the prom- remission in older children). Studies by Tarshish et al
ising results of the previous pilot (phase II) study. To showed that patients with minimal-change nephrotic syn-
obtain a large sample size estimated from the pilot study, drome who were initially frequent relapsers tended to
the patients ranging from 2 years to 19 years were included achieve an infrequent or nonrelapsing course with age
in this trial. The primary analysis, conducted on 97 mizori- [32]. Based on these observations, it is likely that the
bine- and 96 placebo-treated patients, showed that the older subgroup of our study contained patients with a
relapse rate was lower in the mizoribine group than in tendency toward long-term remission without immuno-
the placebo group, but was not significantly different. suppressive drugs.
For the treatment of frequent relapsing and steroid-We analyzed the subgroups in which the test drug was
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Table 3. Adverse events
Mizoribine Placebo
(N 5 99) (N 5 98)
Hyperuricemia 16 4
Hepatic dysfunction 9 9
Alopecia 3 2
Leukocytopenia 2 1
Leukocytosis 1 2
Anemia 0 1
Hyperlipidemia 0 2
Headache 2 0
Hypertension 1 0
Aphthous stomatitis 1 1
Nausea 1 0
Chest discomfort 1 0
Finger tremor 1 0
BUN increased 1 0
Serum creatinine increased 1 0
Hypocomplemetemia 1 0
Edema 0 1
Urticaria 0 1
Tonsillitis 1 0
Varicella 0 1
Urinary tract infection 1 0
Ureteral calculus 1 0
The occurrence of adverse events was 33% (33/99) in the mizoribine group
and 21% (21/98) in the placebo group.
Fig. 4. Distribution of the relapse risk index in the subgroup of patients
by age at the start of the trial.
suppressive drugs in its ability to decrease the relapse
rate. However, the baseline characteristics of patients,
duration of the study period, and numbers of patientsdependent nephrotic syndrome, cytotoxic or immuno-
suppressive drugs such as cyclophosphamide, chloram- differed from study to study. A comparative study be-
tween immunosuppressive/cytotoxic agents would be de-bucil, cyclosporine, and levamisole have been used to
induce a lasting remission and prevent further exposure sirable to clarify the superiority among these drugs.
The acute side effects and long-term risks of treatmentto steroids. There are few placebo-controlled studies to
elucidate the relapse reducing effect of an immunosup- with steroids or immunosuppressive/cytotoxic agents are
a matter of concern. Our study as well as others showedpressive/cytotoxic drug in children with FRNS [9, 33]. A
multicenter, double-blind study in Japan [33], including that mizoribine is a safe drug [26–28]. The most common
side effect was an increase in serum uric acid levels,108 children (under 15 years old) with FRNS, reported
that during 24-week administration of the test drugs, which was noted in previous studies [28], as well as our
open trial (unpublished observations) and this study.50% patients in the cyclosporine group (N 5 49) and
70% patients in the placebo group (N 5 59) developed Hyperuricemia tended to develop in the early phase of
the treatment and soon disappeared in most cases with-relapse. The relapse rate during the study period was
0.0054 and 0.0099 in the cyclosporine group and the out stopping the drug. The increase in uric acid in the
plasma can be derived from the action of this drug toplacebo group, respectively, thus reaching a relapse rate
ratio of 0.55 (95% CI, 0.37 to 0.82, P 5 0.003) in this inhibit the synthesis of guanine nucleotide [16, 17]. There
were no significant differences in the prevalence of otherplacebo-controlled cyclosporine study. The data in our
subgroup consisting of children aged 10 years or younger adverse events between mizoribine and placebo groups.
Low frequency in serious side effects of mizoribine may(relapse rate 0.0052 in mizoribine vs. 0.0078 in placebo,
ratio 0.66, 95% CI, 0.44 to 0.94, P 5 0.017) seemed to be attributed to its pharmaceutical characteristics. Mi-
zoribine is metabolized to its monophosphate form bybe close but not superior to the cyclosporine data. In
the previous study comparing levamisole with placebo adenosine kinase [34] and competitively inhibits inosine
monophosphate dehydrogenase and guanosine mono-in children (N 5 61) with steroid-dependent nephrotic
syndrome, 55 and 87% patients had relapsed by the end phosphate synthase, enzymes required for de novo syn-
thesis of guanine nucleotides from inosine monophos-of the 16-week test period [9]. Compared with the result
in our subgroup (children #10 years old), the percentage phate [16, 17]. Purine synthesis in lymphocytes depends
exclusively on the de novo pathway. Thus, mizoribinein remission by the time to relapse in the levamisole
study was low in the test drug group as well as the placebo strongly inhibits the proliferation of lymphocytes, but
rarely affects the proliferation of other cells, where agroup. Mizoribine may be compared with other immuno-
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of action of the immunosuppressive drug mizoribine. J Clin Investsalvage pathway is used for purine synthesis. Uptake of
87:940–948, 1991
mizoribine into nucleic acids does not occur because 18. Hirohata S, Yanagida T: Inhibition of expression of cyclin A in
phosphorylation ceases at the level of monophosphates human B cells by an immunosuppressant mizoribine. J Immunol
155:5175–5183, 1995[35, 36]. Therefore, it is less likely that mizoribine shows
19. Kamada H, Inoue N, Takaoka Y, Nakagami K, Mori H, Nagaisuch carcinogenicity as reported for azathioprine and H: Effect of mizoribine on effector T cell-mediated immune re-
cyclophosphamide. In conclusion, this drug can be worth sponses in mice. Biol Pharm Bull 19:1136–1140, 1996
20. Kamada H, Itoh H, Shibata H, Koshio T, Hayashi A, Nakagamiconsidering as an alternative to the treatment with alkyl-
K: Inhibitory mechanism of mizoribine on the antibody productionating or immunosuppressive agents. of mouse B cells stimulated with lipopolysaccharide. Jpn J Pharma-
col 74:323–330, 1997
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